Centene (CNC) Draws Fresh Interest As Margin Recovery Puts Valuation Back In Focus

Renewed interest in Centene (CNC) has been sparked by a cluster of upbeat fund letters and analyst updates citing better-than-expected earnings, improving medical cost trends, and visible progress on margin recovery after recent pressure.

Centene’s recent earnings beats and margin repair story have played out in the share price too, with the stock up 48.68% on a year-to-date share price basis and delivering a 73.81% total shareholder return over the past year. However, the 3-year and 5-year total shareholder returns of 9.94% and 1.46% declines indicate that this recovery is still rebuilding a longer track record.

Scan other insurers that show similar earnings momentum and margin repair to Centene by exploring our curated list of 31 resilient stocks with low risk scores.

After a near 50% year-to-date move, Centene now sits in the awkward middle ground between a turnaround story and a mature insurer rerating. Is the valuation still pointing to upside, or has most of the recovery already been priced in?

Most Popular Narrative: 13.5% Undervalued

Centene’s most followed narrative pegs fair value at $71.78 per share versus a last close of $62.12, highlighting a clear gap between the current quote and what that storyline assumes the business is worth.

Company wide cost structure work, including an adjusted SG&A ratio of 6.9% in Q2 2026 and a targeted US$480 million of SG&A savings from workforce and enterprise optimization, along with AI enabled fraud and legal cost controls, supports the case that lower overhead and medical cost leakage can feed directly into higher operating margins.

See why 57 investors see Centene as 13% undervalued.

Result: Fair Value of $71.78 (UNDERVALUED)

Still, the Centene story can change if policy shifts weaken Medicaid funding or if Marketplace support, such as premium tax credits, rolls off faster than expected.

Find out about the key risks to this Centene narrative.

Next Steps

Mixed signals around Centene can either boost conviction or create doubt, so move quickly, review the full picture, and weigh the 3 key rewards and 1 important warning sign.

Looking for more Centene style investment ideas?

If Centene’s rebound has you thinking bigger, use the Simply Wall Street Screener to spot other opportunities before they move without you.

• Target resilient value by zeroing in on financially strong companies through our curated 31 high quality undervalued stocks.
• Spot durable cash flows and cleaner balance sheets using the focused list of solid balance sheet and fundamentals (25 results).
• Hunt for earlier stage potential by scanning the 19 high quality undiscovered gems before they hit the broader radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com